Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. (BIXT) is a clinical-stage biotechnology company whose news flow centers on antiviral drug development, oxygen transport therapies, and advances in stroke and Alzheimer’s research. Company press releases describe a pipeline that includes ProLectin-M, PHM23, and BXT-25, along with collaborations and scientific milestones that support these programs.
News updates frequently highlight clinical trial progress for ProLectin-M, an oral galectin antagonist antiviral being developed under an active IND with the FDA. Bioxytran has reported completion of randomized, double-blind, placebo-controlled trials and dose optimization studies, with endpoints focused on viral load reduction, symptom improvement, and safety. Releases also discuss regulatory interactions with agencies such as the FDA and India’s Central Drugs Standard Control Organization for future trial design.
Another recurring theme in Bioxytran’s news is its oxygen therapeutics platform. The company issues updates on BXT-25 and the Universal Oxygen Carrier project, including securing a GMP-quality source of camel hemoglobin through a joint venture with the Heme Foundation. Articles describe how this work ties into research on mitochondrial function, tissue oxygenation, and the use of the MDX Viewer as a real-time diagnostic tool in stroke and neurodegenerative disease studies.
Bioxytran’s news also covers scientific recognition and partnerships, such as the inclusion of its antiviral PHM23 in a University of Georgia grant submission for Bird Flu research, and publications by scientific advisors on oxygen homeostasis and brain models of ischemic stroke. In addition, the company has announced initiation of independent research coverage of its stock, reflecting interest from micro-cap and small-cap equity research specialists.
Investors and observers who follow BIXT news can expect updates on clinical trial milestones, regulatory submissions, scientific publications, collaborations with academic and nonprofit partners, and developments in its galectin-based antiviral and oxygen transport platforms.
Bioxytran, Inc. (OTCQB: BIXT) announced positive results from its Phase 2 clinical trial involving a Galectin Antagonist for treating COVID-19. The study showed complete elimination of viral load in 100% of patients by day 7, compared to only 6% in the placebo group (p=.001). Additionally, 88% reached this result by day 3. There were no serious adverse events, and no viral rebounds were observed within 14 days. The trial supports plans for a Phase 2/3 registrational study and showcases the drug's novel mechanism of action against viral entry.
Bioxytran announced that its Scientific Advisor, Prof. Avraham Mayevsky, published a book titled Cortical Spreading Depression of Leão: From Mitochondrial Function to Brain Metabolic Score. This work is linked to Bioxytran’s Hypoxia platform technology, which utilizes the MDX Viewer for measuring tissue oxygenation. The technology aims to enhance drug development by providing real-time data on oxygen consumption in tissues, potentially revolutionizing clinical trials. Bioxytran is focusing on its leading drug, ProLectin-M, targeting unmet medical needs in virology and hypoxia.
Bioxytran, a clinical stage biotechnology company, announced a peer-reviewed article supporting its oral antiviral drug, ProLectin-M, published in the International Journal of Health Sciences. The article outlines the drug's mechanism of action (MOA) as a galectin-3 antagonist, confirming initial clinical data showing viral load reduction to undetectable levels in COVID-19 patients. ProLectin-M targets the SARS-CoV-2 virus and demonstrates promising preclinical results with non-toxic levels in humans. Bioxytran aims to address significant unmet medical needs in virology.